No Data
Jiangzhong Pharmaceutical (600750.SH): The controlling Shareholder has obtained a commitment letter for a special loan for Shareholding in Stocks.
On December 10, Gelonghui reported that Jiangzhong Pharmaceutical (600750.SH) announced that on December 9, 2024, it received a notice from its controlling shareholder China Resources Jiangzhong Pharmaceutical Group Co., Ltd. (hereinafter referred to as "China Resources Jiangzhong"). China Resources Jiangzhong has recently obtained a loan commitment letter issued by the Nanchang Donghu Branch of the Industrial And Commercial Bank Of China (hereinafter referred to as "ICBC Nanchang Donghu Branch"). ICBC Nanchang Donghu Branch intends to provide a loan limit of no more than 0.084 billion yuan to China Resources Jiangzhong for its shareholding increase plan, with a loan term of 12 months.
China Resources Pharmaceutical Group's Unit Posts Higher Profit in January-September
Jiangzhong Pharmaceutical Report for the Third Quarter of 2024
Jiangzhong Pharmaceutical Sees Profit Growth Amid Revenue Dip
ChinahTa Pharmaceuticals (03320): jiangzhong pharmaceutical achieved a net income of 0.684 billion yuan in the first three quarters, an increase of 8.98% year-on-year.
Chinare Pharma (03320) announced that on October 25, 2024, jiangzhong pharmaceutical released its financial results for the year ending 202...
Jiangzhong Pharmaceutical (600750.SH): Acquiring 51% equity of Jiangzhong Yinpian for 86.1238 million yuan.
GeLongHui October 25th | jiangzhong pharmaceutical (600750.SH) announced that, in order to explore the layout of upstream resources of traditional chinese medicine, improve the construction of the traditional chinese medicine industry chain, reduce related party transactions, jiangzhong pharmaceutical intends to sign an "equity transfer agreement" with CR JiangZhong, to purchase 51% equity of JiangZhong Yinpian held by CR JiangZhong for 86.1238 million yuan.
